Tag: letrozoleFemara

Articles

• Aromatase inhibitor treatment and weight gain
• Foods to eat & avoid during aromatase inhibitor treatment
• Impact of endocrine therapy (hormone therapy) on BC prognosis
• Lobular breast cancer and LCIS characteristics

News

04/30/13

Side effects of anti-estrogens can indicate treatment is working

12/31/12

Treatment with Femara after tamoxifen can worsen cholesterol profile

07/19/12

Aromatase inhibitors are less effective in women with high BMI

09/07/11

Strongly ER+ lobular breast cancer responds well to Femara

07/17/11

Increasing aromatase inhibitor side effects make tamoxifen attractive

11/18/10

Aromatase inhibitors have many potential side effects

Studies

• Delayed versus immediate use of zoledronic acid for postmenopausal patients with ER/PR positive early breast cancer who are using adjuvant letrozole. Cite
  Abdel Gelil M. Delayed versus immediate use of zoledronic acid for postmenopausal patients with ER/PR positive early breast cancer who are using adjuvant letrozole.. JCO Global Oncology. American Society of Clinical Oncology (ASCO); 2023; 9:8-8 10.1200/go.2023.9.supplement_1.8
• Effects of letrozole on serum estradiol and estrone in postmenopausal breast cancer patients and tolerability of treatment: a prospective trial using a highly sensitive LC–MS/MS (liquid chromatography–tandem mass spectrometry) method for estrogen measurement Cite
  Faltinová M, Vehmanen L, Lyytinen H, Haanpää M, Hämäläinen E, Tiitinen A, et al. Effects of letrozole on serum estradiol and estrone in postmenopausal breast cancer patients and tolerability of treatment: a prospective trial using a highly sensitive LC–MS/MS (liquid chromatography–tandem mass spectrometry) method for estrogen measurement. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2023; 10.1007/s10549-023-07054-3
• In Vitro Effects of Combining Genistein with Aromatase Inhibitors: Concerns Regarding Its Consumption during Breast Cancer Treatment Cite
  Bezerra PHA, Amaral C, Almeida CF, Correia-da-Silva G, Torqueti MR, Teixeira N. In Vitro Effects of Combining Genistein with Aromatase Inhibitors: Concerns Regarding Its Consumption during Breast Cancer Treatment. Molecules. MDPI AG; 2023; 28:4893 10.3390/molecules28134893
• Obesity and metabolic syndrome are associated with short-term endocrine therapy resistance in early ER + breast cancer Cite
  Bergman R, Berko YA, Sanchez V, Sanders ME, Gonzalez-Ericsson PI, Arteaga CL, et al. Obesity and metabolic syndrome are associated with short-term endocrine therapy resistance in early ER + breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2022; 10.1007/s10549-022-06794-y
• Gingerol/letrozole-loaded mesoporous silica nanoparticles for breast cancer therapy: In-silico and in-vitro studies Cite
  Akbarzadeh I, Poor AS, Khodarahmi M, Abdihaji M, Moammeri A, Jafari S, et al. Gingerol/letrozole-loaded mesoporous silica nanoparticles for breast cancer therapy: In-silico and in-vitro studies. Microporous and Mesoporous Materials. Elsevier BV; 2022;:111919 10.1016/j.micromeso.2022.111919
• Abstract P5-18-12: Cardioprotective effects of walnuts against aromatase inhibitor: Pilot study in a zebrafish model Cite
  Hilakivi-Clarke L, Da Silva JL, Blaes A, Hoeppner L. Abstract P5-18-12: Cardioprotective effects of walnuts against aromatase inhibitor: Pilot study in a zebrafish model. Cancer Research. American Association for Cancer Research (AACR); 2022; 82:P5-18-12-P5-18-12 10.1158/1538-7445.sabcs21-p5-18-12
• Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials Cite
  Bradley R, Braybrooke J, Gray R, Hills RK, Liu Z, Pan H, et al. Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials. The Lancet Oncology. Elsevier BV; 2022; 10.1016/s1470-2045(21)00758-0
• Letrozole Accelerates Metabolic Remodeling through Activation of Glycolysis in Cardiomyocytes: A Role beyond Hormone Regulation Cite
  Heo JH, Lee SR, Jo SL, Yang H, Lee HW, Hong E. Letrozole Accelerates Metabolic Remodeling through Activation of Glycolysis in Cardiomyocytes: A Role beyond Hormone Regulation. International Journal of Molecular Sciences. MDPI AG; 2022; 23:547 10.3390/ijms23010547
• Impact of Nigella Sativa on body weight, volume and weight of ovary in Letrozole Induced POS in Mice Cite
  Anwar N, Nadeem A, Naheed K, Arshad Jarral S, Saad Abdullah M, Asad A, et al. Impact of Nigella Sativa on body weight, volume and weight of ovary in Letrozole Induced POS in Mice. Pakistan Journal of Medical and Health Sciences. Lahore Medical and Dental College; 2021; 15:2355-2357 10.53350/pjmhs211592355
• Dietary Supplement Use and Interactions with Tamoxifen and Aromatase Inhibitors in Breast Cancer Survivors Enrolled in Lifestyle Interventions Cite
  Harrigan M, McGowan C, Hood A, Ferrucci LM, Nguyen T, Cartmel B, et al. Dietary Supplement Use and Interactions with Tamoxifen and Aromatase Inhibitors in Breast Cancer Survivors Enrolled in Lifestyle Interventions. Nutrients. MDPI AG; 2021; 13:3730 10.3390/nu13113730
• Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy Cite
  Jerusalem G, Farah S, Courtois A, Chirgwin J, Aebi S, Karlsson P, et al. Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy. Annals of Oncology. Elsevier BV; 2021; 32:1256-1266 10.1016/j.annonc.2021.07.017
• Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial Cite
  Del Mastro L, Mansutti M, Bisagni G, Ponzone R, Durando A, Amaducci L, et al. Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial. The Lancet Oncology. Elsevier BV; 2021; 10.1016/s1470-2045(21)00352-1
• Monitoring serum estradiol levels in breast cancer patients during extended adjuvant letrozole treatment after five years of tamoxifen: a prospective trial Cite
  Faltinová M, Vehmanen L, Lyytinen H, Haanpää M, Hämäläinen E, Tiitinen A, et al. Monitoring serum estradiol levels in breast cancer patients during extended adjuvant letrozole treatment after five years of tamoxifen: a prospective trial. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2021; 10.1007/s10549-021-06168-w
• Clinical behavior of recurrent hormone receptor–positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1‐98 clinical trial Cite
  Leone JP, Cole BF, Regan MM, Thürlimann B, Coates AS, Rabaglio M, et al. Clinical behavior of recurrent hormone receptor–positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1‐98 clinical trial. Cancer. Wiley; 2020; 10.1002/cncr.33318
• Letrozole and zoledronic acid changed signalling pathways involved in the apoptosis of breast cancer cells Cite
  Sheweita SA, Ammar RG, Sabra SA, Sultan AS. Letrozole and zoledronic acid changed signalling pathways involved in the apoptosis of breast cancer cells. Journal of Taibah University Medical Sciences. Elsevier BV; 2020; 10.1016/j.jtumed.2020.10.017
• Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial Cite
  Smith I, Robertson J, Kilburn L, Wilcox M, Evans A, Holcombe C, et al. Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial. The Lancet Oncology. Elsevier BV; 2020; 21:1443-1454 10.1016/s1470-2045(20)30458-7
• Abstract 1441: Aspirin in combination with Letrozole or Olaparib induced apoptosis in estrogen receptor-positive T-47D & triple negative MDA-MB-231 breast cancer cell lines Cite
  Kamel MESE, Sheweita SA, Sultan AS. Abstract 1441: Aspirin in combination with Letrozole or Olaparib induced apoptosis in estrogen receptor-positive T-47D & triple negative MDA-MB-231 breast cancer cell lines. Immunology. American Association for Cancer Research; 2020; 10.1158/1538-7445.am2020-1441
• Association between BMI, vitamin D, and estrogen levels in postmenopausal women using adjuvant letrozole: a prospective study Cite
  Elliott MJ, Ennis M, Pritchard KI, Townsley C, Warr D, Elser C, et al. Association between BMI, vitamin D, and estrogen levels in postmenopausal women using adjuvant letrozole: a prospective study. npj Breast Cancer. Springer Science and Business Media LLC; 2020; 6 10.1038/s41523-020-0166-y
• The Role of Previous Therapies and Sites of Metastasis as Influencing Factors on Discordance of ER, PR and HER2 Status Between Primary and Metastasized Breast Cancer Cite
  VOGEL C, MALTER W, MORGENSTERN B, LUDWIG S, VEHRESCHILD JJ, HAMACHER S, et al. The Role of Previous Therapies and Sites of Metastasis as Influencing Factors on Discordance of ER, PR and HER2 Status Between Primary and Metastasized Breast Cancer. Anticancer Research. Anticancer Research USA Inc.; 2019; 39:2647-2659 10.21873/anticanres.13389
• Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial Cite
  Mamounas EP, Bandos H, Lembersky BC, Jeong J, Geyer CE, Rastogi P, et al. Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology. Elsevier BV; 2019; 20:88-99 10.1016/s1470-2045(18)30621-1
• Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial Cite
  Ruhstaller T, Giobbie-Hurder A, Colleoni M, Jensen M, Ejlertsen B, de Azambuja E, et al. Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2019; 37:105-114 10.1200/jco.18.00440
• Clinical outcomes comparison of 10 years versus 5 years of adjuvant endocrine therapy in patients with early breast cancer Cite
  Li L, Chang B, Jiang X, Fan X, Li Y, Li T, et al. Clinical outcomes comparison of 10 years versus 5 years of adjuvant endocrine therapy in patients with early breast cancer. BMC Cancer. Springer Science and Business Media LLC; 2018; 18 10.1186/s12885-018-4878-4
• Metabolomics Reveals that Dietary Xenoestrogens Alter Cellular Metabolism Induced by Palbociclib/Letrozole Combination Cancer Therapy Cite
  Warth B, Raffeiner P, Granados A, Huan T, Fang M, Forsberg EM, et al. Metabolomics Reveals that Dietary Xenoestrogens Alter Cellular Metabolism Induced by Palbociclib/Letrozole Combination Cancer Therapy. Cell Chemical Biology. Elsevier BV; 2018; 25:291-300.e3 10.1016/j.chembiol.2017.12.010
• Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial Cite
  Colleoni M, Luo W, Karlsson P, Chirgwin J, Aebi S, Jerusalem G, et al. Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. The Lancet Oncology. Elsevier BV; 2018; 19:127-138 10.1016/s1470-2045(17)30715-5
• Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05) Cite
  Blok EJ, Kroep JR, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, Putter H, van den Bosch J, et al. Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05). JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2017; 110:40-48 10.1093/jnci/djx134
• Comparison of the effects of nobiletin and letrozole on the activity and expression of aromatase in the MCF-7 breast cancer cell line Cite
  Rahideh ST, Keramatipour M, Nourbakhsh M, Koohdani F, Hoseini M, Talebi S, et al. Comparison of the effects of nobiletin and letrozole on the activity and expression of aromatase in the MCF-7 breast cancer cell line. Biochemistry and Cell Biology. Canadian Science Publishing; 2017; 95:468-473 10.1139/bcb-2016-0206
• Abstract P2-09-14: Association between BMI and residual estradiol levels in post-menopausal women using adjuvant letrozole: Results of a prospective study Cite
  Cescon D, Ennis M, Pritchard K, Townsley C, Warr D, Elser C, et al. Abstract P2-09-14: Association between BMI and residual estradiol levels in post-menopausal women using adjuvant letrozole: Results of a prospective study. Poster Session Abstracts. American Association for Cancer Research; 2017; 10.1158/1538-7445.sabcs16-p2-09-14
• Randomized, blinded trial of vitamin D3 for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS) Cite
  Shapiro AC, Adlis SA, Robien K, Kirstein MN, Liang S, Richter SA, et al. Randomized, blinded trial of vitamin D3 for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS). Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2016; 155:501-512 10.1007/s10549-016-3710-6
• Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence Cite
  Chirgwin JH, Giobbie-Hurder A, Coates AS, Price KN, Ejlertsen B, Debled M, et al. Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016; 34:2452-2459 10.1200/jco.2015.63.8619
• Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years Cite
  Goss PE, Ingle JN, Pritchard KI, Robert NJ, Muss H, Gralow J, et al. Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. New England Journal of Medicine. Massachusetts Medical Society; 2016; 375:209-219 10.1056/nejmoa1604700
• Effects of vitamin D and calcium supplementation on side effects profile in patients of breast cancer treated with letrozole Cite
  Arul Vijaya Vani S, Ananthanarayanan P, Kadambari D, Harichandrakumar K, Niranjjan R, Nandeesha H. Effects of vitamin D and calcium supplementation on side effects profile in patients of breast cancer treated with letrozole. Clinica Chimica Acta. Elsevier BV; 2016; 459:53-56 10.1016/j.cca.2016.05.020
• Effects of letrozole on breast cancer micro-metastatic tumor growth in bone and lung in mice inoculated with murine 4T1 cells Cite
  Wang W, Belosay A, Yang X, Hartman JA, Song H, Iwaniec UT, et al. Effects of letrozole on breast cancer micro-metastatic tumor growth in bone and lung in mice inoculated with murine 4T1 cells. Clinical & Experimental Metastasis. Springer Science and Business Media LLC; 2016; 33:475-485 10.1007/s10585-016-9792-z
• MicroRNA-206, let-7a and microRNA-21 pathways involved in the anti-angiogenesis effects of the interval exercise training and hormone therapy in breast cancer Cite
  Isanejad A, Alizadeh AM, Amani Shalamzari S, Khodayari H, Khodayari S, Khori V, et al. MicroRNA-206, let-7a and microRNA-21 pathways involved in the anti-angiogenesis effects of the interval exercise training and hormone therapy in breast cancer. Life Sciences. Elsevier BV; 2016; 151:30-40 10.1016/j.lfs.2016.02.090
• Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial Cite
  Metzger Filho O, Giobbie-Hurder A, Mallon E, Gusterson B, Viale G, Winer EP, et al. Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2015; 33:2772-2779 10.1200/jco.2015.60.8133
• A nude mouse model of obesity to study the mechanisms of resistance to aromatase inhibitors Cite
  Schech A, Yu S, Goloubeva O, McLenithan J, Sabnis G. A nude mouse model of obesity to study the mechanisms of resistance to aromatase inhibitors. Endocrine-Related Cancer. Bioscientifica; 2015; 22:645-656 10.1530/erc-15-0168
• New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane Cite
  HOLE S, PEDERSEN AM, HANSEN SK, LUNDQVIST J, YDE CW, LYKKESFELDT AE. New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane. International Journal of Oncology. Spandidos Publications; 2015; 46:1481-1490 10.3892/ijo.2015.2850
• Extra virgin olive oil potentiates the effects of aromatase inhibitors via glutathione depletion in estrogen receptor-positive human breast cancer (MCF-7) cells Cite
  Ismail AM, In LL, Tasyriq M, Syamsir DR, Awang K, Omer Mustafa AH, et al. Extra virgin olive oil potentiates the effects of aromatase inhibitors via glutathione depletion in estrogen receptor-positive human breast cancer (MCF-7) cells. Food and Chemical Toxicology. Elsevier BV; 2013; 62:817-824 10.1016/j.fct.2013.10.024
• Prediction of Late Disease Recurrence and Extended Adjuvant Letrozole Benefit by the HOXB13/IL17BR Biomarker Cite
  Sgroi DC, Carney E, Zarrella E, Steffel L, Binns SN, Finkelstein DM, et al. Prediction of Late Disease Recurrence and Extended Adjuvant Letrozole Benefit by the HOXB13/IL17BR Biomarker. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2013; 105:1036-1042 10.1093/jnci/djt146
• The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L) Cite
  Wasan K, Goss P, Pritchard P, Shepherd L, Palmer M, Liu S, et al. The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L). Annals of Oncology. Elsevier BV; 2005; 16:707-715 10.1093/annonc/mdi158
• Lipid concentrations in postmenopausal women on letrozole after 5 years of tamoxifen: an NCIC CTG MA.17 sub-study Cite
  Wasan KM, Goss PE, Pritchard PH, Shepherd L, Tu D, Ingle JN. Lipid concentrations in postmenopausal women on letrozole after 5 years of tamoxifen: an NCIC CTG MA.17 sub-study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2012; 136:769-776 10.1007/s10549-012-2294-z
• The citrus flavonone hesperetin prevents letrozole-induced bone loss in a mouse model of breast cancer Cite
  Li F, Chow S, Cheung W, Chan FL, Chen S, Leung LK. The citrus flavonone hesperetin prevents letrozole-induced bone loss in a mouse model of breast cancer. The Journal of Nutritional Biochemistry. Elsevier BV; 2013; 24:1112-1116 10.1016/j.jnutbio.2012.08.010
• Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results Cite
  Coleman R, de Boer R, Eidtmann H, Llombart A, Davidson N, Neven P, et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Annals of Oncology. Elsevier BV; 2013; 24:398-405 10.1093/annonc/mds277
• Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole Cite
  Goss P, Ingle J, Martino S, Robert N, Muss H, Livingston R, et al. Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole. Annals of Oncology. Elsevier BV; 2013; 24:355-361 10.1093/annonc/mds330
• Suppression of Plasma Estrogen Levels by Letrozole and Anastrozole Is Related to Body Mass Index in Patients With Breast Cancer Cite
  Folkerd EJ, Dixon JM, Renshaw L, A'Hern RP, Dowsett M. Suppression of Plasma Estrogen Levels by Letrozole and Anastrozole Is Related to Body Mass Index in Patients With Breast Cancer. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2012; 30:2977-2980 10.1200/jco.2012.42.0273
• Surgery for widely disseminated breast cancer: prolonged control by excision of metastases Cite
  Rees GJ, Britton DC, Malcolm GP, Rees M. Surgery for widely disseminated breast cancer: prolonged control by excision of metastases. JRSM Short Reports. SAGE Publications; 2012; 3:1-4 10.1258/shorts.2012.011162
• Early operable breast cancer in elderly women treated with an aromatase inhibitor letrozole as sole therapy Cite
  Balakrishnan A, Ravichandran D. Early operable breast cancer in elderly women treated with an aromatase inhibitor letrozole as sole therapy. British Journal of Cancer. Springer Science and Business Media LLC; 2011; 105:1825-1829 10.1038/bjc.2011.470
• Final 5-year results of Z-FAST trial Cite
  Brufsky AM, Harker WG, Beck JT, Bosserman L, Vogel C, Seidler C, et al. Final 5-year results of Z-FAST trial. Cancer. Wiley; 2011; 118:1192-1201 10.1002/cncr.26313
• Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07) Cite
  Zaman K, Thürlimann B, Huober J, Schönenberger A, Pagani O, Lüthi J, et al. Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07). Annals of Oncology. Elsevier BV; 2012; 23:1474-1481 10.1093/annonc/mdr448
• Invasive lobular carcinoma: response to neoadjuvant letrozole therapy Cite
  Dixon JM, Renshaw L, Dixon J, Thomas J. Invasive lobular carcinoma: response to neoadjuvant letrozole therapy. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2011; 130:871-877 10.1007/s10549-011-1735-4
• Toxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients: A Systematic Review and Meta-analysis Cite
  Amir E, Seruga B, Niraula S, Carlsson L, Ocaña A. Toxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients: A Systematic Review and Meta-analysis. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2011; 103:1299-1309 10.1093/jnci/djr242
• Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study Cite
  Briot K, Tubiana-Hulin M, Bastit L, Kloos I, Roux C. Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2009; 120:127-134 10.1007/s10549-009-0692-7
• Dietary genistein negates the inhibitory effect of letrozole on the growth of aromatase-expressing estrogen-dependent human breast cancer cells (MCF-7Ca) in vivo Cite
  Ju YH, Doerge DR, Woodling KA, Hartman JA, Kwak J, Helferich WG. Dietary genistein negates the inhibitory effect of letrozole on the growth of aromatase-expressing estrogen-dependent human breast cancer cells (MCF-7Ca) in vivo. Carcinogenesis. Oxford University Press (OUP); 2008; 29:2162-2168 10.1093/carcin/bgn161
• Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer Cite
  Khan QJ, Reddy PS, Kimler BF, Sharma P, Baxa SE, O’Dea AP, et al. Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2009; 119:111-118 10.1007/s10549-009-0495-x